Original articles

Madah-Amiri D, Skulberg AK, Braarud AC, Dale O, Heyerdahl F, Lobmaier P, Clausen T (2018)
Ambulance-attended opioid overdoses: An examination into overdose locations and the role of a safe injection facility
Subst Abus, 40 (3), 383-388
DOI 10.1080/08897077.2018.1485130, PubMed 29949448

Madah-Amiri D, Clausen T, Lobmaier P (2017)
Rapid widespread distribution of intranasal naloxone for overdose prevention
Drug Alcohol Depend, 173, 17-23
DOI 10.1016/j.drugalcdep.2016.12.013, PubMed 28182982

Madah-Amiri D, Clausen T, Myrmel L, Brattebø G, Lobmaier P (2016)
Circumstances surrounding non-fatal opioid overdoses attended by ambulance services
Drug Alcohol Rev, 36 (3), 288-294
DOI 10.1111/dar.12451, PubMed 28036135

Madah-Amiri D, Clausen T, Lobmaier P (2016)
Utilizing a train-the-trainer model for multi-site naloxone distribution programs
Drug Alcohol Depend, 163, 153-6
DOI 10.1016/j.drugalcdep.2016.04.007, PubMed 27107847

Bukten A, Lund IO, Rognli EB, Stavseth MR, Lobmaier P, Skurtveit S, Clausen T, Kunøe N (2015)
The Norwegian Offender Mental Health and Addiction Study - Design and Implementation of a National Survey and Prospective Cohort Study
Subst Abuse, 9 (Suppl 2), 59-66
DOI 10.4137/SaRt.S23546, PubMed 26648732

Kunøe N, Lobmaier P, Vederhus JK, Hjerkinn B, Gossop M, Hegstad S, Kristensen Ø, Waal H (2010)
Challenges to antagonist blockade during sustained-release naltrexone treatment
Addiction, 105 (9), 1633-9
DOI 10.1111/j.1360-0443.2010.03031.x, PubMed 20707781

Kunøe N, Lobmaier P, Vederhus JK, Hjerkinn B, Hegstad S, Gossop M, Kristensen O, Waal H (2010)
Retention in naltrexone implant treatment for opioid dependence
Drug Alcohol Depend, 111 (1-2), 166-9
DOI 10.1016/j.drugalcdep.2010.03.021, PubMed 20570059

Kunøe N, Lobmaier P, Vederhus JK, Hjerkinn B, Hegstad S, Gossop M, Kristensen Ø, Waal H (2009)
Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial
Br J Psychiatry, 194 (6), 541-6
DOI 10.1192/bjp.bp.108.055319, PubMed 19478295

Review articles

Kunøe N, Lobmaier P, Ngo H, Hulse G (2014)
Injectable and implantable sustained release naltrexone in the treatment of opioid addiction
Br J Clin Pharmacol, 77 (2), 264-71
DOI 10.1111/bcp.12011, PubMed 23088328

Lobmaier P, Gossop M, Waal H, Bramness J (2010)
The pharmacological treatment of opioid addiction--a clinical perspective
Eur J Clin Pharmacol, 66 (6), 537-45
DOI 10.1007/s00228-010-0793-6, PubMed 20169438

Lobmaier P, Kornør H, Kunøe N, Bjørndal A (2008)
Sustained-release naltrexone for opioid dependence
Cochrane Database Syst Rev (2), CD006140
DOI 10.1002/14651858.CD006140.pub2, PubMed 18425938

Other articles

Kunoe N, Lobmaier P, Gossop M, Waal H (2010)
Naltrexone implants Reply
Br. J. Psychiatry, 196 (1), 77

Kunøe N, Lobmaier P (2005)
Blame the counselling, not the implant. A response to Oliver, Horspool & Keen (2005)
Addiction, 100 (7), 1027-8; author reply 1028-9
DOI 10.1111/j.1360-0443.2005.01209.x, PubMed 15955020